List view / Grid view
Digitalisation, R&D and AMR were highlighted as key areas of…
Digitalisation, R&D and AMR were highlighted as key areas of focus to support European competitiveness up to the end of the decade, as set out in new Political Guidelines for Europe.
EFPIA’s reflections on the recent Conclusions of the Special Meeting…
EFPIA’s reflections on the recent Conclusions of the Special Meeting of the European Council assert the importance of ensuring a more resilient and competitive life sciences sector.
Following the recent European Parliament plenary vote, EFPIA asserts that…
Following the recent European Parliament plenary vote, EFPIA asserts that aligning the next revision of the pharmaceutical legislation to increase Europe’s competitiveness will be a challenge.
Pharmaceutical manufacturing in Europe is at risk of critical medicine…
Pharmaceutical manufacturing in Europe is at risk of critical medicine shortages, states the European Federation of Pharmaceutical Industries and Associations (EFPIA), if the widest chemical substance restriction, concerning Per- and Polyfluoroalkyl Substances (PFAS), is put in place.
Industry bodies EPFIA and the Alliance for Regenerative Medicine and…
Industry bodies EPFIA and the Alliance for Regenerative Medicine and law firm Pinsent Masons have responded to the recent proposed revision of the EU pharmaceutical legislation.
Research suggests a Transferable Exclusivity Extension (TEE) system is “the…
Research suggests a Transferable Exclusivity Extension (TEE) system is “the only existing option capable of incentivising antibiotic R&D in a sustainable manner” for Europe.
The EFPIA has published 10 recommendations to ensure that procurement…
The EFPIA has published 10 recommendations to ensure that procurement practices across the EU are effective and sustainable, delivering high quality medicines for patients, in the right quantities and at the right time.
The ABPI and EFPIA have both emphasised the need for…
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
The pharma industry has called for the government to act…
The pharma industry has called for the government to act to ensure that patients receive their medications in the case of a ‘no deal’ situation...
The associations representing the European and British life science industry…
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
